Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

Video

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses the PACIFIC study with durvalumab (Imfinzi) in stage III non–small-cell lung cancer (NSCLC).

The phase 3 PACIFIC trial was a randomized trial that enrolled patients with unresectable stage III NSCLC after completion of concurrent chemoradiation therapy, says Bazhenova. The type of radiation or chemotherapy patients were given was not prescribed by investigators from the PACIFIC study because that treatment was given prior to enrollment, explains Bazhenova. If the patient received chemoradiation therapy and did not progress, they were eligible for enrollment on the trial.

In the trial, patients were randomized 2:1 to receive either durvalumab every 2 weeks for 12 months versus placebo. Results from the study showed that durvalumab improved progression-free survival (PFS) as well as overall survival (OS), says Bazhenova. Specifically, preliminary results indicated that the median PFS was 16.8 months with durvalumab versus 5.6 months with placebo (HR, 0.52; 95% CI, 0.42-0.65; P < .0001). The 12-month PFS rate was 55.9% versus 35.3% with durvalumab versus placebo, respectively, and the 18-month PFS rate was 44.2% versus 27.0%, respectively. The median OS has not yet been reached in the durvalumab arm; however, consistent reports have demonstrated an improvement in OS at 12 months, 24 months, and 36 months, concludes Bazhenova.

Related Videos
Joachim G. J. V. Aerts, MD, PhD
Nathaniel Myall, MD
Martin Cannon, PhD, professor, Department of Microbiology, University of Arkansas for Medical Sciences College of Medicine
Pedro Barata, MD, MSc
In this fourth episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, and Michael W. McDermott, MD, discuss the key objectives of the phase 3 LIMITLESS study (NCT05317858) examining low-intensity focused ultrasound with immunotherapy and chemotherapy in patients with lung cancer and brain metastases.
Brian Mitzman, MD, FACS, FCCP
Yvonne Chao, MD, PhD
Pradnya D. Patil, MD, FACP,
 In this third episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the expanding role of neoadjuvant therapy in non–small cell lung cancer and efforts to better identify patients who can benefit from curative-intent treatment.